Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Lorigerlimab monotherapy in Cancer, Platinum-resistant ovarian cancer. The expected timing is based on the latest available company guidance and may change.
LINNET study. 3/20/25- To initiate LINNET Ph2 study. 5/13/25- First patient dosed. 11/12/25:- Enrollment continues in the LINNET Phase 2 monotherapy study in platinum-resistant ovarian or clear cell gynecologic cancers, and a clinical update on the first part of the trial is expected by Mid-2026. 02/23/26:- FDA placed a partial clinical hold on LINNET; enrollment paused due to Grade 4-5 safety events. 03/09/26:- LINNET partial hold ongoing; company working with FDA; clinical update still expected Mid-2026. 04/08/26:- FDA lifted LINNET partial hold; enrollment to resume. Mid-year 2026 clinical update expected. 05/13/26:- LINNET Ph2 shows 25% ORR in CCGC; PROC cohort discontinued; updated results expected H1 2027. 07/23/26:- LINNET Phase 2 study poster scheduled for ESMO 2026 on October 26, 2026. 08/13/26:- LINNET Ph2 interim data will be presented at ESMO 2026 on October 26, 2026. Updated CCGC results are expected in H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.